Supplementary Figure S3 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab Plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
crossref(2024)
Abstract
Clinical outcome of trial according to treatment and human papilloma virus (HPV) status.
MoreTranslated text
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined